Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 04, 2022 16:45 ET | Source: Applied Genetic Technologies Corporation

AGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the...
March 22, 2022 08:45 ET | Source: Applied Genetic Technologies Corporation

AGTC Announces Pricing of Public Offering of Common Stock

GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development...
March 21, 2022 16:01 ET | Source: Applied Genetic Technologies Corporation

AGTC Announces Proposed Public Offering of Common Stock

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development...
March 08, 2022 16:05 ET | Source: Applied Genetic Technologies Corporation

AGTC to Participate in Upcoming Investor Conferences

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development...
February 14, 2022 07:00 ET | Source: Applied Genetic Technologies Corporation

AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021

-Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass.,...
February 08, 2022 07:00 ET | Source: Applied Genetic Technologies Corporation

AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinical Development of AGTC-401 in Patients with CNGB3 Achromatopsia

AGTC-401 demonstrated a favorable safety profile through second-highest dose (1.1E+12 vg/mL) in ACHMB3 pediatric patientsAt the dose of 1.1E+12 vg/mL greater than 50% of the combined adults and...
February 07, 2022 08:00 ET | Source: Applied Genetic Technologies Corporation

AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development...
January 11, 2022 08:00 ET | Source: Applied Genetic Technologies Corporation

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022Company providing further updated guidance on other...
January 04, 2022 08:00 ET | Source: Applied Genetic Technologies Corporation

AGTC to Participate in the H.C. Wainwright BioConnect 2022 Conference

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development...
December 06, 2021 08:00 ET | Source: Applied Genetic Technologies Corporation

AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the...